The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
|Slideshows|September 18, 2018
Depression Research: Vagus Nerve Stimulation, Omega-3 Supplementation, Adolescent Psychiatry
Author(s)Mark L. Fuerst
New studies in major depression find VNS improves the quality of life of patients with treatment-resistant depression and two other findings.
Advertisement
Advertisement
Related to this article
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5